Nisa Investment Advisors LLC reduced its holdings in Henry Schein, Inc. (NASDAQ:HSIC – Get Rating) by 4.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 36,621 shares of the company’s stock after selling 1,684 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Henry Schein were worth $2,925,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Forsta AP Fonden increased its position in Henry Schein by 1.7% in the 4th quarter. Forsta AP Fonden now owns 35,100 shares of the company’s stock valued at $2,803,000 after acquiring an additional 600 shares during the period. Breakwater Capital Group acquired a new position in Henry Schein in the 4th quarter valued at approximately $251,000. Stock Yards Bank & Trust Co. acquired a new position in Henry Schein in the 4th quarter valued at approximately $236,000. Bank of Montreal Can increased its position in Henry Schein by 32.9% in the 4th quarter. Bank of Montreal Can now owns 79,200 shares of the company’s stock valued at $6,422,000 after acquiring an additional 19,628 shares during the period. Finally, Sendero Wealth Management LLC increased its position in Henry Schein by 74.0% in the 4th quarter. Sendero Wealth Management LLC now owns 5,524 shares of the company’s stock valued at $441,000 after acquiring an additional 2,350 shares during the period. 95.45% of the stock is currently owned by institutional investors and hedge funds.
Henry Schein Trading Up 0.5 %
NASDAQ:HSIC opened at $85.07 on Tuesday. The company has a current ratio of 1.79, a quick ratio of 0.91 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $11.16 billion, a price-to-earnings ratio of 21.87, a PEG ratio of 1.96 and a beta of 0.81. The firm has a fifty day simple moving average of $81.03 and a two-hundred day simple moving average of $79.47. Henry Schein, Inc. has a 12 month low of $64.75 and a 12 month high of $89.72.
Insider Buying and Selling at Henry Schein
In other Henry Schein news, Director Kurt P. Kuehn sold 1,909 shares of the firm’s stock in a transaction on Thursday, March 16th. The shares were sold at an average price of $77.46, for a total value of $147,871.14. Following the transaction, the director now directly owns 15,675 shares of the company’s stock, valued at $1,214,185.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Philip A. Laskawy sold 6,405 shares of the firm’s stock in a transaction dated Friday, March 3rd. The shares were sold at an average price of $78.74, for a total transaction of $504,329.70. Following the transaction, the director now directly owns 26,239 shares of the company’s stock, valued at $2,066,058.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kurt P. Kuehn sold 1,909 shares of the firm’s stock in a transaction dated Thursday, March 16th. The shares were sold at an average price of $77.46, for a total transaction of $147,871.14. Following the transaction, the director now directly owns 15,675 shares in the company, valued at $1,214,185.50. The disclosure for this sale can be found here. Insiders own 1.00% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on HSIC shares. Barrington Research decreased their price objective on shares of Henry Schein from $99.00 to $92.00 and set an “outperform” rating for the company in a research report on Friday, February 17th. Credit Suisse Group decreased their price objective on shares of Henry Schein from $99.00 to $97.00 and set an “outperform” rating for the company in a research report on Tuesday, February 28th. Morgan Stanley decreased their price objective on shares of Henry Schein from $70.00 to $69.00 and set an “underweight” rating for the company in a research report on Tuesday, February 21st. Piper Sandler increased their price objective on shares of Henry Schein from $85.00 to $97.00 and gave the stock an “overweight” rating in a research report on Monday, February 6th. Finally, UBS Group increased their price objective on shares of Henry Schein from $75.00 to $82.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 7th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Henry Schein currently has an average rating of “Hold” and a consensus target price of $85.89.
About Henry Schein
Henry Schein, Inc engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgical, diagnostic tests, infection-control products, and vitamins.
Featured Articles
- Get a free copy of the StockNews.com research report on Henry Schein (HSIC)
- Medtronic: Reversal In-Play For This High-Yield Stock
- Is it ‘Game Over’ for Roblox After Reporting March Metrics Miss?
- Is it Time to Take Profits in Chip Stocks?
- Will Stratasys Continue to be a Runaway Bride?
- Garrett Motion Inc. Skids on Results: Is it Time to Buy the Dip?
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC – Get Rating).
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
